| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |